Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies

Thrombosis Research

Volumn 85, Issue 3, 1997, Pages 177-183

  Zangari, Maurizio ^a   Lockwood, Charles J ^a   Scher, Jonathan ^a   Rand, Jacob H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

antiphospholipid syndrome; F1.2; pregnancy

Indexed keywords

PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ABORTION; ADULT; ARTICLE; BLOOD CLOTTING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; FEMALE; HUMANS; PEPTIDE FRAGMENTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTHROMBIN;

EID: 0031079575     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00002-9     Document Type: Article

References (33)

1. HARRIS EN, GHARAVI AE, BOEY ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. ii:1983;1211-1214.
2. MCNEIL HP, et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2 Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 87:1990;4120.
3. BEVERS EM, GALLI M, BARBUI T, COMFURIUS P, ZWAAL RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only but to a complex of lipid bound prothrombin. Thromb Haemost. 66:1991;629-632.
4. LOCKWOOD CJ, RAND JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obst Gyn Surv. 49:(6):1994;432-441.
5. BAUER KA, ROSENBERG RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood. 70:1987;343-350.
6. BAUER KA, GOODMAN TL, KASS BL, ROSENBERG RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest. 76:1985;826-836.
7. BAUER KA, BROCKMANS AW, BERTINA RM, et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 71:1988;1418-1426.
8. LOIZOU S; MCCREA JD; RUDGE AC; REYNOLDS R et al: Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitiation of results. 62(3), 738-45, 1985.
9. JACKSON CM, NEMERSON Y. Blood coagulation. Ann Rev Bioch. 9:1980;765-811.
10. BOISCLAIR MD, IRELAND H, LANE DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood-Rev. 4:1980;25-40.
11. BAUER KA, ROSENBERG RD. Congenital antithrombin III deficiency: Insights into the pathogenesis of the hypercoagulable state and its management using marker of hemostatic system activation. Am J Med. 87:(3B):1989;39S-43S.
12. ABRAMOWICZ D, PRADIER O, MARCHANT A, FLORQUIN S, DE FAUW L, VEREERSTRAETEN P, KINNAERT P, VANHERWEGHEM JL, GOLDMAN M. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet. 339:(8796):1992;777-778.
13. CERIELLO A, GIACOMELLO R, COLATUTTO A, TABOGA C, GONANO F. Increased prothrombin fragment 1.2 in type I diabetic patients. Haemost. 22:1992;50-51.
14. MANNUCCI PM, BAUER KA, GRINGERI A, BARZEGAR S, BOTTASSO B, SIMONI L, ROSENBERG RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 76:1990;2540-2545.
15. MILLENSON MM, BAUER KA, KISTLER JP, BARZEGAR S, TULIN L, ROSENBERG RD. Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. Blood. 79:1992;2034-2034.
16. MCNEIL HP, CHESTERMAN CN, KRITIS SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Imm. 49:1991;193-280.
17. GALLI M, GRASSI A, BARBUI T. Platelet-derived microvesicles in patients with antiphospholipid antibodies. Thromb Haemost. 69:1993;541a.
18. WANG CT, LIN YL. Synergistic activation of human platelets by anticardiolipin antibodies and epinephrine. Thromb Haemost. 69:1993;917a.
19. MARTINUZZO ME, MACLOUF J, LEVY TOLEDANO S, et al. Effects of antiphospholipid antibodies on eicosanoid biosynthesis and platelet activation in vitro. Thromb Haemost. 69:1993;542a.
20. CARRERAS LO, DEFREYN G, MACHIN SJ, et al. Arterial thrombosis, intrauterine death, and "lupus" anticoagulant: Detection of immunoglobin interfering with prostacyclin formation. Lancet. 1:1981;244-246.
21. DIAZ CREMADES JM, ALSAR MJ, BOSCH JM, et al. Protein S deficiency on (sic)patients with lupus anticoagulant antiphospholipid antibodies. Thromb Haemost. 69:1993;594a.
22. COSGRIFF TM, MARTIN BA. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum. 24:1981;94-96.
23. SAN FELIPPO MJ, DRAYNA CJ. Prekellikrein inhibition associated with lupus anticoagulant. Am J Clin Path. 77:1982;275-279.
24. ITOH YH, YAMANOTO Y, AIHARA M, et al. Effects of IgG fraction in LA positive and APA positive SLE patients on human vein and artery endothelial cells. Thromb Haemost. 69:1993;594a.
25. 2 glycoprotein-I (apolipoprotein H). Proc Nat Acad Sci. 87:1990;3120-4124.
26. 2 glycoprotein-I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost. 68:1992;297-300.
27. NGUYEN AND, TRIPLETT DA, BARA L, et al. Lupus anticoagulant and the phospholipid-prothrombin epitope model. Thromb Haemost. 69:1993;541a.
28. RAND JH, XX WU, GULLER S, GIL J, GUHA A, SCHER J, LOCKWOOD CJ. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obst Gyn. 17:1994;1566-1572.
29. SHIBATA S, HARPEL PC, GHARAVI A, RAND JH, FILLIT H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood. 83:(9):1994;2532-2540.
30. BAUER KA, BARZEGAR S, ROSEMBERG RD, Influence of anticoagulants for blood collection on plasma prothrombin fragment F1+2 measurement. Thromb Res, 63, 617-28, 1981.
31. BRUHN HD, CONARD J, MANNUCCI M, MONTEAGUDO J, PELZER H, REVERTER JC, SAMAMA M, TRIPODI A, WAGNER C. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination. Thromb Haemost. 68:1992;413-417.
32. EICHINGER S, WOLZ M, NIESZPAUR-LOS M, SCHNEIDER B, et al: Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Department of Medicine I, Vienna University Hospital, Austria. Thromb Haemost, 72, 831-5, 1994.
33. CADROY Y, GRANDJEAN J, PICHON J, DESPRATS R, BERREBI A, FOURNIE A, BONEU B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obst Gyn. 100:1993;416-420.